Ger­man court de­nies va­lid­i­ty of Cure­Vac patent claim in fight with BioN­Tech over Covid-19 vac­cine 

A Ger­man court on Tues­day in­val­i­dat­ed a Cure­Vac patent that was part of the biotech’s on­go­ing fight with BioN­Tech over the mR­NA tech­nol­o­gy used in Covid-19 vac­cines.

Had Cure­Vac’s claims been up­held, the biotech could have been in a po­si­tion to re­ceive a frac­tion of BioN­Tech’s Covid-19 vac­cine rev­enues. In­stead, Tues­day’s an­nounce­ment about the Ger­man Fed­er­al Patent Court’s de­ci­sion sent Cure­Vac’s shares $CVAC down 25%.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.